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Abstract. Given the prognostic significance of pathological 
complete response (pCR) to neoadjuvant chemotherapy, 
we sought to chronicle the clinical course of breast cancer 
patients whose tumors exhibited pCR at our institution. We 
retrospectively reviewed 5,533 cancer center patients treated 
for a first primary breast cancer between March, 1999 and 
September, 2010 to identify those who received neoadjuvant 
chemotherapy that resulted in pCR (i.e., no residual invasive 
malignancy in the breast or axilla). The descriptive statistics of 
treatments received, recurrence, morbidity and mortality as of 
October, 2013 were reported. Of the 5,533 patients reviewed, 
86 met the inclusion criteria. The mean age at diagnosis was 
48 years [standard deviation (SD), 9.4 years] and the mean length 
of follow‑up was 68 months (SD, 27 months). The majority of 
the patients underwent axillary lymph node dissection (ALND; 
n=60, 69.8%), received adjuvant radiation therapy (XRT; 
n=72, 83.7%), had poorly differentiated (grade 3) tumors (n=74, 
86.1%) and had pure ductal histology (n=74, 86.1%). A total of 
5 patients (5.8%) developed disease recurrence. All the patients 
who recurred had grade 3 tumors with ductal histology and 
underwent ALND for known pre‑neoadjuvant‑treatment lymph 
node metastases; none received adjuvant chemotherapy. A total 
of 4 patients (4.7%) succumbed to the disease, 3 due to breast 
cancer recurrence <18 months following the initial diagnosis. 
Recurrence following pCR was rare, but when it did occur, 
time- to-recurrence was short at <18 months. All the patients 
who recurred and eventually succumbed to breast cancer 
had axillary metastases at diagnosis, indicating that axillary 
disease is a major negative prognostic factor in patients who 
achieve pCR following neoadjuvant chemotherapy.
Introduction
As our knowledge of the human genome and the molecular 
subtypes of particular cancers increases, the field of breast 
oncology is becoming increasingly focused on individualizing 
treatment based on the clinical and biochemical profile of a 
given patient. Nomograms are being developed and used to 
guide the type and extent of therapy patients receive, with the 
hope that we optimally treat many and overtreat few (1,2). 
As we collectively navigate the path from clinical assess-
ment to individualized treatment to optimized outcome, the 
significance of proximal clinical endpoints must not be under-
estimated, as they assist clinicians in determining whether to 
proceed with or modify a given patient's treatment course and 
may also facilitate pharmaceutical development by providing 
a surrogate endpoint of efficacy that does not mandate the long 
follow‑up periods required to evaluate differences in survival 
or recurrence (3,4).
Pathological complete response (pCR) to neoadjuvant 
chemotherapy has emerged as a reliable prognostic indicator 
for overall and event‑free survival following breast cancer diag-
nosis (5‑10), occurring in ~15‑40% of breast cancer patients 
receiving neoadjuvant chemotherapy (3). Given the prognostic 
significance of pCR and the evolution of decision‑making 
nomograms for the management of breast cancer, we aimed 
to chronicle the clinical course of breast cancer patients at 
our institution (Siteman Cancer Center, St. Louis, MO, USA) 
whose index tumors exhibited pCR.
Patients and methods
Patient selection. Clinical, demographic and pathological data 
from all the breast cancer patients treated at our institution are 
prospectively recorded in a database. In a retrospective review 
of this database, 5,533 patients treated for a first primary 
breast cancer at Siteman Cancer Center between March, 1999 
and September, 2010 were identified. Subsequently, patients 
who received neoadjuvant chemotherapy for treatment of a 
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pathologically confirmed invasive (stages I‑III) breast cancer 
were identified and their medical records were reviewed to 
determine which of these tumors exhibited pCR, defined as no 
evidence of residual invasive malignancy in the breast or axilla. 
As ductal carcinoma in situ (DCIS) generally does not regress 
with chemotherapy and evidence of its effect on prognosis is 
equivocal (11,12), patients with only residual DCIS following 
neoadjuvant chemotherapy were included in the pCR cohort.
Institutional Review Board approval was obtained prior to 
the commencement of this retrospective study at Washington 
University School of Medicine. Written consent from the 
patients was not required, due to the retrospective nature of 
this study.
Statistical analysis. The descriptive statistics of treat-
ments received, recurrence, morbidity and mortality as of 
October, 2013 are reported. All the statistical analyses were 
conducted using SAS 9.3 software (SAS Institute Inc., Cary, 
NC, USA).
Results
Patient characteristics. Of the 5,533 patients reviewed, 
746 received neoadjuvant chemotherapy and 86 (1.6% of all 
patients, 11.5% of neoadjuvant chemotherapy recipients) met 
the inclusion criteria (Table I). The mean age at diagnosis was 
48 years [standard deviation (SD), 9.4 years] and the mean 
length of follow‑up was 68 months (SD, 27 months). The 
majority of the patients underwent axillary lymph node dissec-
tion (ALND; n=60, 69.8%), were Caucasian (n=60, 69.7%), 
received adjuvant radiation therapy (XRT; n=72, 83.7%), had 
poorly differentiated (grade 3) tumors (n=74, 86.1%), had only 
ductal histology (n=74, 86.1%) and received a taxane as part of 
their neoadjuvant treatment (n=83, 96.5%). Due to inconsisten-
cies in the information documentation process in our database, 
the administration of anti‑human epidermal growth factor 
receptor 2 (HER2)/neu treatments could not be determined for 
all patients and, accordingly, summary statistics on this treat-
ment variable were not provided.
Outcome. A total of 5 patients (5.8%) developed disease 
recurrence (1 locoregional and distant and 4 distant recur-
rence) (Table II). The only patient in our cohort with residual 
DCIS developed recurrence. All the patients who recurred had 
grade 3 tumors with ductal histology and underwent ALND 
for known pre‑neoadjuvant treatment lymph node metastases; 
none of the patients with recurrence received adjuvant chemo-
therapy. A total of 4 patients (4.7%) succumbed to the disease, 
3 due to breast cancer recurrence <18 months after the initial 
diagnosis and 1 due to metastatic small bowel adenocarcinoma.
Discussion
High tumor grade and the presence of lymph node metastases 
at diagnosis were two prominent clinical characteristics shared 
by all patients who recurred following pCR. High tumor grade 
has been previously reported as a marker of pCR probability, 
as the high mitotic activity of poorly differentiated tumors 
appears to render them more susceptible to the cytotoxic 
effects of standard chemotherapy regimens (13,14). However, 
this potential vulnerability to chemotherapy lies in tension 
with the fact that high tumor grade has, outside the context 
of pCR, been demonstrated to be a predictor of breast cancer 
progression, recurrence and death (15). This paradox points to 
a greater challenge in therapeutic decision‑making for breast 
cancer patients: Specifically, when trying to determine who is 
Table I. Characteristics of breast cancer patients (n=86) exhib-
iting pCR following neoadjuvant chemotherapy.a
Clinical characteristics Values
Age, years [median (range)] 48 (27‑70)
Follow‑up, months [median (range)] 39 (8‑124)
Race, n (%)
  African American 25 (29.1)
  Asian American 1 (1.2)
  Caucasian 60 (69.7)
Bilaterality, n (%)
  Bilateral 2 (2.3)
  Unilateral 84 (97.7)
Lymph node involvement, n (%)
  Yes 49 (57.0)
  No 37 (43.0)
TNM stage, n (%)
  Early (I‑IIA) 38 (44.2)
  Late (IIB‑IIIC) 48 (55.8)
Receptor status, n (%)
  ER
    Positive 25 (29.1)
    Negative 61 (70.9)
  PR
    Positive 17 (19.8)
    Negative 69 (80.2)
  HER2/neu
    Positive 31 (36.0)
    Negative 55 (64.0)
  ER-/PR-/HER2+ 16 (18.6)
  ER-/PR-/HER2- (triple-negative) 43 (50.0)
Tumor grade, n (%)
  1 2 (2.3)
  2 10 (11.6)
  3 74 (86.1)
Histology, n (%)
  Ductal only 74 (86.1)
  Lobular only 2 (2.3)
  Other 10 (11.6)
aSiteman Cancer Center (March, 1999‑September, 2010). pCR, path-
ological complete response; ER, estrogen receptor; PR, progesterone 
receptor; HER2, human epidermal growth factor receptor 2.
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most likely to experience pCR, one needs to consider not 
only the patients with enhanced susceptibility to neoadjuvant 
therapies, but also the patients who are most likely to benefit 
from these treatments. Patients with grade 3 tumors are at 
the intersection of these two idealized populations: they are 
more likely to have poor outcomes as a result of their disease, 
but they are also more likely to respond to chemotherapeutic 
treatment. Neoadjuvant chemotherapy is generally reserved 
for patients with locally advanced disease (a number of 
whom have tumor biology that precludes systemic endocrine 
therapy) in order to treat disseminated disease and facilitate 
breast conservation therapy (16). However, a recent study 
demonstrating the safety of neoadjuvant systemic therapy in 
early‑stage patients (17) should mitigate concerns regarding the 
administration of preoperative systemic therapy to early‑stage 
patients with poorly differentiated tumors, but displaying 
other disease characteristics that may otherwise have encour-
aged oncologists to forego chemotherapy. Thus, administering 
neoadjuvant chemotherapy to grade 3 patients of all stages may 
significantly affect the rate of pCR and concomitant outcomes, 
although additional clinical trials investigating the efficacy of 
neoadjuvant chemotherapy in early‑stage patients are required.
In addition, there is increasing evidence that a certain 
subset of women with axillary disease at diagnosis require 
adjuvant systemic therapy, regardless of their local response 
to neoadjuvant treatment, as demonstrated on operative 
pathology (18). In our cohort, a total of 5 patients recurred, 3 of 
whom did so within 18 months of definitive surgical treatment; 
none of these 5 patients received adjuvant chemotherapy. Such 
a short interval between diagnosis and post‑treatment recur-
rence likely reflects the failure of neoadjuvant treatment in 
these patients and is further proof that axillary lymph node 
metastases should be considered as markers of disseminated 
disease that may continue to progress regardless of pCR in the 
breast and axilla. In addition, all 5 patients with recurrence 
were aged <50 years at diagnosis, young age being a clinical 
characteristic that compounds the negative prognosticators of 
high grade and axillary disease at diagnosis.
Finally, recent studies have demonstrated the extent to which 
the prognostic accuracy of pCR depends on a given tumor's 
molecular subtype. Specifically, in a large meta‑analysis 
including 7 German randomized trials, von Minckowitz et al 
found that pCR appeared to be a reasonable surrogate 
endpoint for patients with luminal B/HER2-, ER-/PR-/HER2+ 
and triple‑negative biomarker profiles, but not for those 
with luminal B/HER2+ or luminal A tumors (12). However, 
of the 5 patients in our cohort who developed recurrence 
following pCR, 2 had ER-/PR-/HER2+ disease (1 succumbed 
to the disease and 1 remains alive and disease‑free) and 2 had 
triple‑negative disease, both of whom succumbed to their 
cancer. Thus, even for the subset of patients for whom pCR is 
a good prognosticator, its accuracy is not 100%.
Major advances have been made over the past 15 years 
in refining the potential use of pCR with regards to medical 
decision-making for patients with breast cancer. For example, 
it was observed that, although tumors with estrogen and/or 
progesterone receptors are less likely to undergo pCR following 
neoadjuvant systemic therapy, patients with these tumors tend 
to have better long‑term outcomes compared with patients 
with hormone receptor‑negative disease (14,16). Furthermore, 
pCR does not appear to be a useful predictor of outcome for 
assessing the long‑term efficacy of neoadjuvant endocrine 
therapy, which rarely results in pCR (19). As described above, 
we are developing a better sense of the optimal way to inter-
pret and utilize pCR in patients with tumor subtypes for whom 
pCR has been associated with improved outcomes. The next 
rational step in prognostication with pCR would be to further 
delineate which particular molecular subtypes among those 
predisposed to pCR are more likely to recur following pCR 
and the underlying mechanisms. Notably, the only patient 
in our cohort who had residual DCIS following neoadjuvant 
chemotherapy (as allowed for in our inclusion criteria) devel-
oped a recurrence. As proposed in a recent study, the standard 
definition of pCR, in which residual in situ malignancy is 
allowed to be present, may require revision (12). DCIS may 
actually have a greater malignant potential than once thought 
in certain tumor subtypes; in addition, its close proximity to 
overlooked invasive disease may be of greater significance 
than previously appreciated (12). None of the patients who 
recurred received adjuvant therapy, although some may have 
had both known and unknown clinicopathological characteris-
tics, such as residual DCIS, which may have prompted further 
treatment had their tumors not shown pCR. For a subset of 
breast cancer patients who receive neoadjuvant chemotherapy, 
pCR may confer a false sense of confidence that diverts them 
and their oncologists away from the systemic adjuvant treat-
ment that may have otherwise prevented recurrence or even 
saved their lives.
Our findings corroborate previous research demonstrating 
that, while pCR portends promising outcomes for the majority 
of neoadjuvant chemotherapy recipients with breast cancer, 
it holds significantly less prognostic significance for certain 
women, specifically those whose disease lies at the intersec-
tion of multiple negative prognosticators, including high grade, 
preoperative axillary metastases, young age and aggressive 
tumor biology.
Additional prospective studies are warranted to deter-
mine which clinicopathological characteristics mitigate the 
prognostic efficacy of pCR as a predictor of disease‑free and 
overall survival among subtypes (namely, ER-/PR-/HER2+ 
and triple-negative) whose receptor statuses usually lend 
themselves to accurate prognostication by pCR. Such research 
would undoubtedly help with the refinement of treatment 
decision nomograms in women undergoing neoadjuvant 
chemotherapy.
Our study's findings are important for a number of reasons. 
First, to the best of our knowledge, the average length of 
follow‑up for our cohort (68 months) is the longest in the 
literature on pCR in breast cancer, allowing us to demonstrate 
the relative long‑term infrequency of recurrence following 
pCR, while showing that, when recurrence does occur, it 
may happen quite soon following pathological confirmation 
of response. Second, while our study identified characteris-
tics (such as young age and the presence of axillary disease) 
that were found to be associated with post‑pCR recurrence in 
other larger cohorts (20,21) by drilling down on the pretreat-
ment characteristics, received therapies and post‑therapeutic 
course of our patients who recurred following pCR, we have 
identified additional factors (including tumor grade, the pres-
ence of residual DCIS and non‑administration of adjuvant 
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chemotherapy) that may warrant additional investigation, both 
in isolation and in association with each other.
Our study was limited first and foremost by the retrospective 
nature of our review. Women who receive neoadjuvant chemo-
therapy are more likely to have hormone receptor‑negative, 
biologically aggressive tumors, for which the availability of 
alternative treatments is more limited. Accordingly, there is 
significant selection bias in our sample, which was also insuf-
ficient for comparative statistical analysis; we chose not to 
compare the 86 patients who underwent pCR to the 660 who did 
not, as we were concerned that uncontrolled differences between 
these groups would significantly confound attempts at statistical 
comparison. Second, all the patients in our study were treated at 
a high‑volume NCI‑designated Comprehensive Cancer Center, 
although the majority of the patients in this country obtain their 
chemotherapy from non‑academic, community medical oncolo-
gists; thus, the extent to which our patients achieve pCR and the 
reasons why they do so may not reflect the treatment experience 
of the typical breast cancer patient.
In conclusion, first primary breast cancer patients whose 
tumors exhibited pCR following neoadjuvant chemotherapy 
had low rates of breast cancer‑specific mortality and recur-
rence compared to the general population of breast cancer 
patients of similar stage, although when recurrence did occur, 
the time-to-recurrence was often short at <18 months. All the 
patients who recurred and eventually succumbed to breast 
cancer had poorly differentiated tumors with axillary metas-
tases at initial diagnosis, indicating that axillary lymph node 
disease burden may itself be a negative prognostic factor in 
patients with a first primary breast cancer who achieve pCR 
following neoadjuvant chemotherapy.
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